Munther S Alnajjar1,2, Mamoon A Aldeyab3, Michael G Scott4, Mary P Kearney5, Glenda Fleming4, Fiona Glimore4, David Farren5, James C McElnay6. 1. Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK. 2. Department of Clinical Pharmacy, College of Pharmacy, Al Ain University of Science and Technology, Al Ain, United Arab Emirates. 3. School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, UK. 4. Medicines Optimisation Innovation Centre, Trust Headquarters Brettan Hall, Antrim Area Hospital, Antrim, BT41 2RL, Northern Ireland, UK. 5. Area Microbiology Laboratory, Antrim Area Hospital, Antrim, BT41 2RL, UK. 6. Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK. j.mcelnay@qub.ac.uk.
Abstract
PURPOSE: Use of antibiotics can give rise to the selection of resistant bacteria. It remains unclear whether antibiotic use in primary care can influence bacterial resistance incidence in patients when hospitalised. The aim of this study is to explore the impact of prior community antibiotic usage on hospital-detected multidrug-resistant Gram-negative (MRGN) incidence rate. METHODS: This pharmacoepidemiological study was case-control in design, and was carried out in the Antrim Area Hospital (N. Ireland) in two phases. In phase 1, the controls were matched according to: age, gender, admission ward, date of admission, and age-adjusted Charlson co-morbidity index score. During the second phase, controls were selected randomly from the total population of admissions to the hospital over the 2-year study period. RESULTS: In phase 1, multivariate analysis revealed that prior exposure to the second- and third-generation cephalosporins (p = 0.004) and fluoroquinolones (p = 0.023) in primary care was associated with an increased likelihood of MRGN detection in inpatients. In phase 2, an independent relationship between an increased risk of identification of MRGN, while hospitalised was associated with: prolonged hospitalisation (p < 0.001), being elderly (p < 0.001), being female (p = 0.007), and having genitourinary disease (p < 0.001). CONCLUSION: This study provides clear evidence which supports the need to optimise antibiotic use in primary care to help reduce MRGN incidence in hospitalised patients.
PURPOSE: Use of antibiotics can give rise to the selection of resistant bacteria. It remains unclear whether antibiotic use in primary care can influence bacterial resistance incidence in patients when hospitalised. The aim of this study is to explore the impact of prior community antibiotic usage on hospital-detected multidrug-resistant Gram-negative (MRGN) incidence rate. METHODS: This pharmacoepidemiological study was case-control in design, and was carried out in the Antrim Area Hospital (N. Ireland) in two phases. In phase 1, the controls were matched according to: age, gender, admission ward, date of admission, and age-adjusted Charlson co-morbidity index score. During the second phase, controls were selected randomly from the total population of admissions to the hospital over the 2-year study period. RESULTS: In phase 1, multivariate analysis revealed that prior exposure to the second- and third-generation cephalosporins (p = 0.004) and fluoroquinolones (p = 0.023) in primary care was associated with an increased likelihood of MRGN detection in inpatients. In phase 2, an independent relationship between an increased risk of identification of MRGN, while hospitalised was associated with: prolonged hospitalisation (p < 0.001), being elderly (p < 0.001), being female (p = 0.007), and having genitourinary disease (p < 0.001). CONCLUSION: This study provides clear evidence which supports the need to optimise antibiotic use in primary care to help reduce MRGN incidence in hospitalised patients.
Authors: J M López-Lozano; D L Monnet; A Yagüe; A Burgos; N Gonzalo; P Campillos; M Saez Journal: Int J Antimicrob Agents Date: 2000-02 Impact factor: 5.283
Authors: A Gallini; E Degris; M Desplas; R Bourrel; M Archambaud; J-L Montastruc; M Lapeyre-Mestre; A Sommet Journal: J Antimicrob Chemother Date: 2010-09-27 Impact factor: 5.790
Authors: Conan MacDougall; J Patrick Powell; Christopher K Johnson; Michael B Edmond; Ronald E Polk Journal: Clin Infect Dis Date: 2005-06-28 Impact factor: 9.079
Authors: Robert Antonio Ramiarina; Beatriz Luiza Ramiarina; Renan Moritz V R Almeida; Wagner Coelho de Albuquerque Pereira Journal: Rev Saude Publica Date: 2008-08 Impact factor: 2.106
Authors: J Rodríguez-Baño; M D Navarro; L Romero; M A Muniain; M de Cueto; J Gálvez; E J Perea; A Pascual Journal: Clin Microbiol Infect Date: 2007-11-15 Impact factor: 8.067
Authors: B S Cooper; G F Medley; S P Stone; C C Kibbler; B D Cookson; J A Roberts; G Duckworth; R Lai; S Ebrahim Journal: Proc Natl Acad Sci U S A Date: 2004-06-25 Impact factor: 11.205